However, we did not find any analysis with detailed comparison of immunochemotherapy effectiveness and safety between patients with PD-L1 expression <1% vs. 1-49%, taking into account tumour histology, as presented in our manuscript. This evidence concerns the gene CD274 and neoplasm.